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ABSTRACT 
Idiosyncratic drug-induced liver injury (DILI) is a rare, often difficult to predict adverse reaction with 
complex pathomechanisms. However, it is now evident that certain forms of DILI are immune-
mediated and may involve the activation of drug-specific T-cells. Exosomes are cell-derived vesicles 
that carry RNA, lipids and protein cargo from their cell of origin to distant cells, and may play a role 
in immune activation. Herein, primary human hepatocytes were treated with drugs associated with 
a high incidence of DILI (flucloxacillin, amoxicillin, isoniazid and nitroso-sulfamethoxazole) to 
characterize the proteins packaged within exosomes that are subsequently transported to dendritic 
cells for processing. Exosomes measured between 50-100 nm and expressed enriched CD63.  LC-
MS/MS identified 2109 proteins, with 608 proteins being quantified across all exosome samples. 
Data are available via ProteomeXchange with identifier PXD010760. Analysis of gene ontologies 
revealed that exosomes mirrored whole human liver tissue in terms of the families of proteins 
present, regardless of drug treatment. However, exosomes from nitroso-sulfamethoxazole-treated 
hepatocytes selectively packaged a specific subset of proteins. LC-MS also revealed the presence of 
hepatocyte-derived exosomal proteins covalently modified with amoxicillin, flucloxacillin and 
nitroso-sulfamethoxazole. Uptake of exosomes by monocyte-derived dendritic cells occurred 
silently, mainly via phagocytosis, and was inhibited by latrunculin A. An, amoxicillin-modified 9-mer 
peptide derived from the exosomal transcription factor protein SOX30 activated naïve T-cells from 
HLA-A*02:01 positive human donors. Conclusion. This study shows that exosomes have the potential 
to transmit drug-specific hepatocyte-derived signals to the immune system and provides a pathway 
for the induction of drug hapten-specific T-cell responses. 
 
INTRODUCTION 
Drug-induced liver injury (DILI) is a complex, multistep and sometimes fatal adverse drug reaction 
(1). While type A reactions can be explained by the pharmacology of the drug, the molecular 
mechanisms of type B or idiosyncratic reactions remain the focus of intensive research. Idiosyncratic 
DILI is rare and difficult to predict; hence, it is reasonable to assume that these reactions are 
associated with specific patient risk factors. Genome-wide association studies have linked specific 
human leukocyte antigens (HLA) to DILI, and as HLA molecules present antigenic determinants to T-
cells, the genetic studies implicate the adaptive immune system in the disease pathogenesis. 
Adverse reactions to amoxicillin clavulanate (2), flucloxacillin (3), lapatinib (4), lumiracoxib (5), 
minocycline (6), ticlopidine (7) and ximelagatran (8) are all associated with a specific risk allele. 
Although the exact role of drug-specific T-cells in DILI is not fully understood, recent studies have 
detected drug-specific T-cells in (i) the peripheral blood (9-11) and (ii) liver biopsies from patients 
with DILI (12, 13). Similarly, T-cells have also been shown to induce cytotoxicity of hepatocyte-like 
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cells transfected with the risk allele HLA-B*57:01 (13). It is often assumed that antigenic and stress-
related signals from the liver are important for adaptive immune stimulation in patients with DILI; 
however, the origin and mechanism of transmission of these signals are difficult to define after 
systemic drug exposure (14). Since primary human hepatocytes are the principle target for DILI 
drugs, we hypothesize that they transmit drug-specific or at least drug-dependent signals to the 
immune system (15). Hence, the purpose of this study was to characterize the proteins encapsulated 
within exosomes derived from hepatocytes treated with DILI drugs and whether exosomes deliver 
drug-specific signals to dendritic cells that subsequently activate the adaptive immune system.   
 
Exosomes, are membrane-bound nano vesicles that originate from the endosomal compartment. 
They are either degraded by lysosomes or secreted into the extracellular space upon fusion with the 
plasma membrane (16). The biogenesis, cargo sorting and ubiquitin-dependent degradation of 
exosomes are regulated by a combination of ESCRTs and multiprotein complexes (17, 18). These 
vesicles transport functional macromolecular components from their cells of origin to distant cells, 
and are thought to play an important role in intercellular communication (19). Although the 
biogenesis of exosomes is conserved in eukaryotes, Kruger et al demonstrated significant differences 
in proteomic and miRNA profiles of exosomes derived from MCF-7 and MDA-MB 231 cells (20). In 
addition the composition of exosomes can be regulated by factors like infection, stress and disease 
(21-22). Therefore, it is plausible that the sorting and packaging of hepatocyte-derived exosomes 
may be influenced by drug exposure, disease state and/or the unique phenotype of patients with 
drug-induced liver injury. 
 
Interestingly, tumour-derived exosomes transport multiple membrane-bound and soluble factors 
that supress the function of human cytotoxic CD4+ and CD8+ T-cells (23). Administration of the 
immunotherapeutic agent, IRX-2 was shown to protect CD8+ T-cells from tumour-derived exosome-
induced apoptosis, resulting in enhanced T-cell-mediated anti-tumour activity (24). Paradoxically, 
the ability of exosomes to cross the cell membrane has also been explored for targeted drug delivery 
systems in cancer immunotherapy (25). 
 
A dogma of drug immunogenicity research is that the binding of drugs to cellular proteins induces a 
tissue-specific signature to direct the immune response. In this respect, exosomes have the potential 
to transport drug-modified proteins from hepatocytes to dendritic cells for protein processing and 
ultimately the display of antigenic peptides. Thus, this study aimed to: (1) characterise protein 
profiles of hepatocyte-derived exosomes and identify specific drug modifications; and (2) explore the 
cellular uptake of hepatocyte-derived exosomes and the impact of this process on dendritic cell 
function and T-cell activation.  
 
EXPERIMENTAL PROCEDURES 
Isolation of hepatocytes from human liver tissue 
Liver biopsies from consenting donors were used for primary human hepatocyte isolation. Biopsies 
were first perfused with HEPES buffer for 20-30 min. This was followed by tissue digest using 
collagenase type IV (Sigma Aldrich, UK). Hepatocytes were harvested using Williams E medium and 
washed twice by gradient centrifugation for 5 min, at 4oC and 80 x g. Hepatocytes were cultured in 
Williams E supplemented with L-glutamine (2 mM), penicillin (100 µg/ml), streptomycin (100 U/ml), 
insulin-transferin-selenium (100x), and dexamethasone (1 µM/ml) using 6 well plates pre-coated 
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with collagen-I (Corning Flintshire, UK). Cells were then maintained in fresh culture media overnight 
before exposure to test drugs for 24 h. 
 
Drug hepatocyte treatment and isolation of exosomes from culture supernatant 
Culture supernatant from hepatocytes treated with sub-toxic concentrations of amoxicillin (0.05 
mM), flucloxacillin (0.05 mM), isoniazid (0.03 mM) and nitroso-sulfamethoxazole (0.01 mM) (26) was 
collected for exosome isolation after 24 h and cells were lysed in RIPA buffer for further proteomic 
analysis. Amoxicillin, flucloxacillin and isoniazid were soluble in cell culture media while nitroso 
sulfamethoxazole was dissolved in 0.05% DMSO. The vehicle cell culture media contained 0.05% 
DMSO. Hepatocytes from 3 donors were used for the analysis. Supernatant was first centrifuged at 
3000g for 15min to remove debris. Afterwards, supernatant was gently mixed with ExoQuick-TC 
solution (5:1; System Biosciences, Palo Alto, Canada). The mixture was incubated at 4 oC for 12 h. 
Samples were then centrifuged at 1500g for 30 min. Supernatant was discarded and the tubes were 
centrifuged for a further 5 min. Exosomes pellets were suspended in either RIPA buffer or PBS. 
 
Transmission electron microscopy  
The exosome suspension was placed on formvar-coated copper grids for 20 minutes then washed 
several times with PBS. Exosomes were then fixed by placing grids on drops of 2% glutaraldehyde on 
parafilm for 5min. Exosomes were contrasted and embedded by transferring grids to 2% uranyl 
acetate for 5 min then adding a drop of 0.13% methyl cellulose and 0.4% uranyl acetate for 5 
minutes. The grids were visualized using a Philips EM 208S transmission electron microscope at 80kv 
and images captured with a Gatan CCD camera. 
 
Assessment of the expression of human exosomal markers and the presence of drug-modified 
exosomal proteins 
20 µg of protein was separated using 12 %SDS-PAGE (170 V, 75 min) and transferred onto a 
nitrocellulose blotting paper (230 mA, 1 h). After blocking, blots were incubated in primary 
antibodies specific for CD9, CD63, CD81 and Hsp70 (System Biosciences, Palo Alto, Canada) 
overnight. Anti-rabbit and anti-goat HRP-conjugated secondary antibodies were then applied and 
the proteins were visualised using enhanced chemoluminescence substrate (Perkin Elmer, 
Netherlands).  
 
Assessment of drug-modified exosomal proteins 
Drug-modification within exosomes was visualized by immunoblotting using rabbit anti-flucloxacillin 
(custom antibody, Eurogentec, Belgium), rabbit anti-nitroso-sulfamethoxazole; 1:2000 (Panigen, 
USA) and mouse anti-penicillin (AbD Serotec, USA) antibodies. 
 
Proteomic profiling of hepatocyte-derived exosomes 
To investigate changes in exosomal protein expression and drug modification of exosomal proteins, 
protein lysates were separated using 12%SDS-PAGE (27). Each lane was rehydrated in 10 ng/µl 
trypsin solution and incubated at 37oC overnight. The peptides were extracted and dried in a 
SpeedVac, followed by resuspension in 10 µl 0.1% formic acid for LC-MS/MS analysis. Samples were 
delivered into a Triple TOF 6600 mass spectrometer (Sciex) by automated in-line reversed phase 
liquid chromatography. A gradient of 2-50 % (v/v) ACN, 0.1 % (v/v) formic acid over 90 min was 
applied to the column at a flow rate of 300 nL/min. Spectra were acquired automatically in positive 
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ion mode using information-dependent acquisition powered by Analyst TF 1.7 software (Sciex), using 
mass ranges of 400-1800 atomic mass units (amu) in MS and 100-1500 amu in MS/MS. Up to 25 
MS/MS spectra were acquired per cycle using a threshold of 300 counts per sec, with dynamic 
exclusion for 12 secs and rolling collision energy. 
 
Proteomic data analysis 
Proteins were identified by ProteinPilot software v5.0 (Sciex) using the ParagonTM algorithm and the 
SwissProt database with biological modifications allowed. The mass tolerance for both precursor and 
fragment ions was 10 ppm. The data were also searched against the reversed database and only 
proteins that fell within a 1% global false discovery rate were included in further analyses. 
 
Two approaches were used to assess potential differences in the exosomal protein profile as a result 
of each of the drug treatments. The decision to use two independent approaches for the data analysis 
was based on the observed heterogeneity of the hepatocyte donors and the passage of time between 
the acquisition of the first dataset and the last.  
 
In approach 1, peptide intensities for each protein derived from ProteinPilot were summed and 
normalised to total ion count for each exosome sample. The data were sorted in RStudio (version 
3.4.0) to produce a composite list of proteins present in every sample and log10 transformed. In 
approach 2, the data were analysed using label-free quantification in MaxQuant (28): all settings 
used were default apart from the minimal LFQ ratio count being set to 1 and the retention time 
window being increased to 5 minutes. The data were searched using human UniProt database. The 
MaxQuant output file was edited to remove contaminants and proteins matching the reverse 
database. The mass spectrometry proteomics data have been deposited to the ProteomeXchange 
Consortium via the PRIDE (29) partner repository with the dataset identifier PXD010760. 
 
Data generated were then subjected to further analysis using the Partek Genomics Suite (version 
7.18.0130). Hierarchical cluster analysis was performed using standardisation, whilst a correlative 
Principal Component Analysis was performed assuming all variables had an equal influence on the 
principal components. The data were then batch corrected for donor and the above analyses were 
repeated. Two-way ANOVA analysis was performed on the uncorrected data with drug treatment 
and donor as variables. Proteins significantly associated with drug treatment were classified using 
PANTHER.  
 
Characterisation of the uptake of hepatocyte-derived exosomes by human monocyte-derived 
dendritic cells 
Antibody-conjugated magnetic bead separation was used to isolate CD14+ monocytes from healthy 
donor PBMC. Monocytes were then cultured with IL-4 (800 U/mL) and GM-CSF (800 U/mL) for 7 days 
to generate dendritic cells. To assess the uptake of hepatocyte-derived exosomes by dendritic cells, 
exosomes were first stained with PKH26 red fluorescent dye (Sigma-Aldrich, UK). Dendritic cells were 
then cultured with dye-stained exosomes on cover slips embedded in 12 well cell culture plates. In 
other experiments dendritic cells were cultured with exosomes isolated from hepatocytes exposed 
to either flucloxacillin or nitroso-sulfamethoxazole for 24 h followed by confocal microscopy to 
determine exosome uptake. 
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Dendritic cells were rinsed and fixed with 4% paraformaldehyde. After rinsing and permeabilisation, 
dendritic cells were incubated with primary antibodies; mouse anti-actin; 1:50 (Santa Cruz 
Biotechnology) and rabbit anti-flucloxacillin or rabbit anti-nitroso-sulfamethoxazole antibodies 
overnight at 4oC. Actin was visualized using Alexa Fluor chicken anti-mouse 488 1:500 (molecular 
probes), while flucloxacillin and nitroso-sulfamethoxazole were visualized using Alexa Fluor chicken 
anti-rabbit 1:500 . Nuclei were stained with Dapi (Invitrogen, 5 µg/ml). Cells were visualized using a 
confocal microscope (Zeiss LSM 800, Germany) and dendritic cells uptake of hepatocyte-derived 
exosomes quantified using Fiji software. The amount of hepatocyte-derived exosomes taken up by 
dendritic cells was estimated by selecting exosomes within a representative field of view and the 
fluorescence intensity measured. 
 
Flow cytometry assessment of activation and maturation markers on dendritic cells exposed to 
test drugs and drug-modified exosomes  
To access the effect of hepatocyte-derived exosomes on dendritic cell activation and maturation, 
dendritic cells were cultured with exosomes derived from hepatocyte exposed to either cell culture 
media or the test compounds flucloxacillin and nitroso-sulfamethoxazole. In order to investigate the 
direct effect of soluble drug on dendritic cell surface markers, dendritic cells were also exposed to 
soluble flucloxacillin (0.05 mM) and nitroso-sulfamethoxazole (0.01 mM) for 24 h. Drug-induced 
changes in the expression of MHC class II, CD40, CD80, CD83 and HLA-DR expression were analysed 
by flow cytometry using FACS Canto IITM system. A total of 10,000 events were acquired. 
 
Peptide design and generation of amoxicillin-modified HLA-A*02:01 binding 9-mer peptides 
Peptide binding prediction of MHC class I peptide epitopes for exosomal proteins was performed 
using the NetMHCpan Server 4.0 search criteria.  The search parameters included restriction to 9mer 
peptides, the HLA-A*02:01 or the HLA-B*57:01 allele and the threshold for strong binders was set to 
0.5%. Epitopes which ranked below 0.5% which contained a central modified residue were 
considered for immunogenicity studies. Finally, due to cysteine containing peptides being difficult to 
synthesise, these were excluded from the suitability criteria. The peptide SLLEPSVKI was chosen for 
the immunogenicity studies and was purchased with and without an Fmoc protection group on the 
n-terminus from Synpeptide Ltd. The n-terminus was protected to ensure site specific modification 
of the lysine at position 8 during synthesis.  
 
Fmoc-SLLEPSVKI was incubated with amoxicillin at a 50:1 molar ratio in 70%ACN/ 30%H2O for 48 
hours at 37oC. Analytes were acidified to 0.1% TFA and loaded onto a Phenomenex C18 Kinetex 5µm 
column coupled with an Agilent 1200 HPLC at λ214. The following HPLC gradient was applied over 30 
minutes: (minutes, %B; 0, 2; 20, 75, 20.10, 98; 25, 98; 25.10, 2; 30, 2) with solvent A as 0.1% TFA and 
solvent B as ACN/ 0.1% TFA. The modified peptide peak was identified through a series of HPLC 
experiments to identify candidate peptide peaks. Fractions were collected and pooled from several 
HPLC runs, this was followed by the addition of piperidine at a 10:1 molar ratio in 70%ACN/ 30%H2O 
for 24 hours to remove the Fmoc protecting group. The incubation was subjected to the same HPLC 
conditions to purify the deprotected drug-modified peptide. A full scheme of peptide purification 
and optimisation is shown in Supplementary Figure 3. Detection of the drug-modified peptide peak 
was analysed using LC-MS/MS. Samples were resuspended in 0.1% FA/ 2%ACN and loaded onto an 
AB Sciex TripleTof 5600 mass spectrometer for analysis. Peptides were manually sequenced using 
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PeakView 1.2 and annotated with the peptide sequence, modified amino acids and characteristic 
fragment ions of amoxicillin.  
 
Determination of the activation of naïve human T-cells from healthy HLA-A*02:01+ donors with an 
amoxicillin-modified SLLEPSVKI peptide  
PBMC from HLA*02:01+ healthy human donors were used to assess the T-cell immunogenicity of the 
amoxicillin-modified SLLEPSVKI peptide. Briefly, PBMC were isolated from venous blood of 3 
donors using density centrifugation. This was followed by separation of CD14 positive monocytes 
and naïve T-cells using antibody-conjugated magnetic beads. Dendritic cells were generated from 
the CD14+ monocytes with a cocktail of IL-4 and GM-CSF over 7 days. On day 7, dendritic cells were 
loaded with unmodified (50 µM) or amoxicillin-modified (50 µM) SLLEPSVKI peptide for 6h 
followed by maturation with LPS and TNF-α overnight. Naïve T-cells (2x105/well; 24-32 wells per 
condition depending on the availability of naïve T-cells) were co-cultured with either with 
unmodified or amoxicillin-modified peptide pulsed dendritic cells (8x103) for 14 days. T-cells were 
then restimulated with a fresh batch of autologous dendritic cells loaded with the unmodified or 
amoxicillin-modified peptide. T-cell proliferative responses were evaluated through the addition of 
3[H]-thymidine incorporation for the final 16 h of the experiment.  
 
Statistical analysis 
 ANOVA or paired t test were used for statistical analysis. P < 0.05 was considered statistically 
significant. 
 
RESULTS 
Morphology and proteomic characterisation of hepatocyte-derived exosomes 
The hepatocyte-derived exosomes measured ≤ 100 nm in diameter (figure 1A) (19).  Immunoblotting 
revealed the expression of CD63 but not CD81, CD9 and Hsp70 (figure 1B). Furthermore, CD63 was 
overexpressed in the exosomal fraction compared to the cell lysate.LC-MS analysis identified 
peptides consistent with CD63, CD81, CD9 and Hsp70 protein expression.  
 
On average, approximately 1200 proteins were identified by LC-MS in untreated hepatocyte-derived 
exosomes across three donors (figure 1C). Comparison of the control hepatocyte exosome proteome 
with that of the whole liver (in-house database of 4739 proteins) revealed that they shared a similar 
protein profile based on molecular function, biological process, cellular component, protein class 
and pathway (figure 1D). Furthermore, exosomes expressed high-mobility group box 1 (HMGB1) and 
heat shock proteins (HSPs) that play important roles in inflammation (30).  
 
Characterisation of global drug-induced changes in proteins packaged by hepatocyte-derived 
exosomes 
When all data files were processed together using ProteinPilot, 2109 proteins were identified within 
an FDR of 1% (Supplementary Table 1 and in the PRIDE repository PXD010760). One third of the 
proteins identified have previously been published in the ExoCarta database (exocarta.org). There 
was a subset of 522 proteins for which there was intensity data in every sample (approach 1). 
MaxQuant identified 1571 proteins within an FDR of 1%, for which there was quantitative data in 
every sample for 608 proteins (approach 2). The data were subjected to hierarchical, PCA and 
ANOVA analysis using Partek Genomics Suite. Samples treated with nitroso-sulfamethoxazole 
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appeared to cluster away from the other samples when the data were processed using either 
approach 1 (Figures 2A and 2C) or approach 2 (Figure 2B and 2D). Two-way ANOVA analysis 
identified 148 proteins from approach 1 and 113 proteins from approach 2 that were significantly 
(P<0.05) associated with the nitroso-sulfamethoxazole treatment. Thirty five of these proteins were 
present in both datasets (Supplementary Figure 1) and are listed in Supplementary Table 2. 
Comparing each drug treatment individually to the control exosome sample revealed few significant 
changes (amoxicillin, 3 proteins; flucloxacillin, 10 proteins; isoniazid, 7 proteins) (Supplementary 
Tables 3A, B and C).  However, the nitroso sulfamethoxazole sample compared to the control sample 
exhibited 35 differentially encapsulated proteins (Supplementary Table 3D). These overlapped 
(23/35) with the analysis of nitroso-sulfamethoxazole compared to all the other treatments 
combined. PANTHER analysis of the list of 35 proteins revealed that most of them are involved in 
catalytic activity (Figure 2E) and that this included a range of enzyme classes (Figure 2F).  
 
Covalent modification of exosomal proteins by amoxicillin, flucloxacillin and nitroso- 
sulfamethoxazole 
Immunoblotting with drug-specific antibodies detected nitroso-sulfamethoxazole and flucloxacillin 
adducts within hepatocyte-derived exosomes (Figure 3A). Furthermore, LC-MS/MS analysis of 
exosomes revealed amoxicillin modification of lysine residues on human transcription factor SOX30, 
albumin and apolipoprotein E (Figures 3B, 4A and 4B). Flucloxacillin-modified peptides from albumin 
were also observed (Figures 3C, 4A and C). In addition, sulphinamide and N-hydroxysulphinamide 
adducts on serotransferrin (Figures 3A, 4A and 4D) and transthyretin (figures 4A and 4E), 
respectively, were detected for nitroso- sulfamethoxazole-treated samples. Interestingly, both 
cysteine residues (C28 and C260) on human serotransferrin that were shown to have been modified 
by nitroso sulfamethoxazole would normally be present as disulphides with other cysteine residues. 
Figures 4A-E show a list of all the drug modified peptides identified and the structure of the proteins 
with sites of modification highlighted. 
 
Human monocyte-derived dendritic cell uptake of exosomes by phagocytosis and endocytosis  
Dendritic cells were found to engulf both unmodified and drug-modified hepatocyte-derived 
exosomes (figure 5A-C and supplementary figure 2A). Figure 5A shows exosomes stained with PKH26 
red fluorescent dye, while figures 5B and 5C show red staining with anti-flucloxacillin and anti-
nitroso- sulfamethoxazole antibodies, respectively. Pre-treatment of dendritic cells with either 
latrunculin-A (phagocytosis inhibitor), dynasore (endocytosis inhibitor) or both inhibitors for 2 h 
before addition of hepatocyte-derived exosomes for 24 h resulted in a significant reduction or 
inhibition of exosome uptake (figure 5D-G and supplementary figure 2B).  
 
Effect of hepatocyte-derived exosomes on the activation of human monocyte-derived dendritic 
cells 
Hepatocyte-derived exosomes did not significantly alter the expression of either dendritic cell 
maturation or activation markers (Figure 6). Furthermore, flucloxacillin and nitroso-
sulfamethoxazole exposure did not interfere with the expression of most markers. However, as 
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described previously, nitroso-sulfamethoxazole treatment resulted in a significant increase in the 
expression of CD40 (31). Binding of CD40 on antigen presenting cells to CD40L on helper T-cells 
activates the antigen presenting cells leading to a pro-inflammatory response (32). Dendritic cell IFN-
 and IL-10 secretion were also assessed by ELIspot after drug or exosome treatment. No significant 
increase in secretion of either cytokine was observed. 
 
Activation of naïve T-cells from HLA-A*02:01 human donors with the amoxicillin-modified 9-mer 
peptide SLLEPSVKI  
Assessing the immunogenicity of whole proteins or exosomes per se was not possible. Therefore, 
peptides containing the drug-modified residues identified on the exosomal proteins, aligned to 
relevant HLA binding epitopes were synthesised to assess their immunogenicity. To do this, protein 
sequences were expanded to include 10 amino acids in both directions from the modified residue 
and these sequences were inputted into the NetMHCpan 4.0 server to search for potential MHC 
class I epitopes. Drug-induced liver injury to amoxicillin and flucloxacillin are associated with the 
class I alleles HLA-A*02:01 and HLA-B*57:01 respectively, while SMX has not shown any specific 
association with HLA alleles. Therefore, these alleles were selected to assess potential peptide 
epitopes for all four modified proteins. Peptide epitopes were selected for study if they scored less 
than 0.5 on the NetMHCpan 4.0 server and only if the modified residue fell within the anchor motifs. 
No peptide epitopes met this selection criteria for HLA-B*57:01, while, strong binding epitopes for 
HLA-A*02:01 were identified for the amoxicillin-modified SOX30 transcription factor protein 
(SLLEPSVKI – NetMHCpan 4.0 Score = 0.047) and the amoxicillin-modified apolipoprotein e protein 
(FLAGCQAKV – NetMHCpan 4.0 Score = 0.128). Both epitopes contained a modified lysine in position 
8 falling within the P2 and PΩ anchors for HLA-A*02:01, however, the apolipoprotein peptide 
sequence also contained a central cysteine residue. Previous studies synthesising drug-modified 
peptides have shown that free cysteines cause difficulty due to peptide dimerization during 
synthesis resulting in low product yield and multiple oxidation states complicating assay variability. 
As such, the amoxicillin-modified peptide epitope for HLA-A*02:01, SLLEPSVK(Amox)I derived from 
SOX30 was the only epitope which met suitable criteria for immunogenicity studies (Figure 7A). The 
unmodified and amoxicillin-modified peptides  yielded the expected peptide fragmentation pattern, 
with characteristic fragments for amoxicillin including a peak at 160 da indicative of the cleaved 
thiazolidine ring and a peak at 349 da indicative of the whole cleaved amoxicillin molecule. Several 
drug-modified fragment peaks were also identified (Figure 7 B-C; Supplementary figure 3). 
 
Naïve T-cells isolated from three HLA-A*02:01 positive donors were co-cultured with autologous 
monocyte-derived dendritic cells that had been pulsed with either unmodified or amoxicillin-
modified SLLEPSVKI peptide, derived from the transcription factor protein SOX30, for 2 weeks. 
The primed T-cells were then restimulated with a second batch of  peptide-loaded dendritic cells 
prior to detection of proliferation using [3H] thymidine. Naïve T-cells from the amoxicillin-modified 
peptide-primed cultures were stimulated to proliferate when restimulated with the amoxicillin-
modified peptide (Figure 7D; p<0.0001). In contrast, no proliferative response was observed in 
similar experiments using dendritic cells pulsed with the unmodified peptide. 
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DISCUSSION 
Idiosyncratic drug reactions targeting the liver are a major challenge for patients, clinicians and the 
pharmaceutical industry as there is currently no way to accurately predict which individuals will 
develop tissue injury. This is partly because the adverse reactions are associated with individual 
susceptibility factors. The discovery of (1) strong associations between DILI and expression of 
specific HLA alleles and (2) the selective drug-specific activation of T-cells from patients with DILI 
indicates that the adaptive immune system is involved in the disease pathogenesis. However, the 
reason why a drug activates T-cells that target the liver has not been defined. One possibility is that 
drugs that induce liver injury form covalent adducts with critical hepatic proteins and that these 
adducts are taken up and processed within dendritic cells prior to presentation of the derived 
peptides to T-cells. Activation of the T-cells within the vicinity of the covalently-modified hepatic 
proteins would result in localized tissue damage. Given the importance of exosomes in the cross talk 
between tissue cells and the immune system and the accumulation of T-cells in liver of patients with 
early stage tissue injury (12, 13), we sought to understand the impact of drug exposure on the 
selective packaging and sorting of hepatocyte components into exosomes, and the interaction 
between hepatocyte-derived exosomes and immune cells. Of particular importance was the detailed 
assessment of exosomal proteins to identify sites of drug modification. Our study focused on three 
of the drugs commonly associated with idiosyncratic DILI in humans: amoxicillin, flucloxacillin and 
isoniazid (26). Although primary human hepatocytes express drug metabolising enzymes for up to 24 
h (33), each drug selected has been shown to forms adducts with lysine residues on protein 
spontaneously, with no requirement for drug metabolism (34-36). Furthermore, we utilized nitroso-
sulfamethoxazole, a synthetic metabolite of sulfamethoxazole that binds covalently to cysteine 
residues (37).  Drug-responsive T-cells have been isolated from the peripheral blood of DILI patients 
exposed to each of these drugs, confirming the immune pathogenesis (9-11). 
 Global analysis of the hepatocyte exosome proteome identified 2109 proteins; of these, one third 
(681) of the proteins have previously been published in the ExoCarta database, which includes 5402 
exosomal proteins derived from all tissues. Those listed in the database as having been derived from 
human liver (326 proteins) were predominantly identified in hepatocellular carcinoma cell lines. Of 
these, only 60 proteins were observed in the dataset presented here. This indicates that the 
exosome proteome derived from freshly isolated hepatocytes is markedly different to that of cancer 
cell lines. This study has provided the most complete proteome for hepatocyte-derived exosomes to 
date. 
 
Comparison of the hepatocyte-derived exosome proteome with the whole liver proteome revealed 
that the distribution of proteins in terms of function, class and pathways was essentially the same 
between the two sources of hepatic material. This suggested that proteins were passively captured 
rather than selectively packaged into the vesicles. Whilst there is evidence for enrichment of RNA 
species and certain membrane-associated proteins in exosomes, the case for cytosolic proteins is 
less clear. When intraluminal vesicles are formed, they encapsulate cytosolic proteins in their lumen 
which remain in place as the vesicle matures into an exosome (38). Data presented here does indeed 
suggest that the hepatocyte exosome proteome provides a snapshot of the cytosolic proteome.  
 
In order to determine whether drug treatment of hepatocytes resulted in a different subset of 
proteins being packaged and exported, a label-free, semi-quantitative analysis was performed. 
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Exosomes isolated from hepatocytes exposed to nitroso-sulfamethoxazole were most dissimilar. 
Thirty five proteins were revealed to be associated with the nitroso-sulfamethoxazole-treated 
sample Since the data presented here suggest that the exosomal proteome reflects the cellular 
proteome from which it is derived, we can extrapolate that the catalytic makeup of the hepatocyte is 
altered by treatment with nitroso-sulfamethoxazole. Several enzymes involved in xenobiotic 
metabolism, including epoxide hydrolase, UDP glucuronyl transferase and arylacetamide 
deacetylase, are present at lower levels in the exosomes from nitroso-sulfamethoxazole-treated 
hepatocytes. This suggests a possible dysfunction in pathways involved in response to chemical 
stress on treatment with the metabolite of sulfamethoxazole.  
 
Drug protein adducts play an important role in immune activation. T-cells from patients with 
flucloxacillin- and amoxicillin clavulanate-induced DILI and sulfamethoxazole hypersensitivity can be 
activated via a pathway that is dependent on the processing of the protein adducts (9, 10). Recently, 
Sanchez-Gomez et al demonstrated that amoxicillin forms adducts with cellular proteins and that 
these adducts are detectable in exosomes found in B-cell culture supernatant (39). Hence, the 
exosome proteome derived from drug-treated hepatocytes was screened for drug modification. 
Adducts of amoxicillin, flucloxacillin and nitroso-sulfamethoxazole were detected on a total of five 
exosomal proteins. One of these, albumin, is targeted in vitro and in vivo by different -lactam 
antibiotics and the modified protein stimulates patient T-cells in vitro (9, 34, 36). These data support 
the hypothesis originally proposed by Sanchez-Gomez et al that drug-modified proteins are 
encapsulated and transported within exosomes to the extracellular matrix. Importantly, however, 
the data also identifies hepatic protein targets modified by DILI drugs that might be critical for T-cell 
activation.  
 
In order for haptenated proteins to trigger an immune response, they must be taken up by antigen 
presenting cells, processed and presented to T-cells in an HLA-restricted manner. Exosomes were 
shown to be internalized by both phagocytosis and endocytosis. Exosomes containing nitroso-
sulfamethoxazole- and flucloxacillin-modified proteins were also internalized. Hence, our data show 
that exosomes transfer tissue-derived drug-modified proteins that have the potential to act as 
neoantigens.  
 
To investigate whether drug-modified exosomal proteins activate T-cells, we utilized in silico peptide 
HLA binding software to identify the 9-mer peptide sequence containing an amoxicillin modification 
that was most likely to bind to HLA-A*02:01 (an HLA class I allele associated with amoxicillin-
clavulanate-induced liver injury (2)). Restimulation of amoxicillin-modified peptide primed T-cells 
with peptide-loaded dendritic cells resulted in a significant proliferative response in all three donors. 
In contrast, the unmodified peptide subjected to the same extraction protocol did not activate the 
patient T-cells. These data demonstrate that the adducts generated in hepatocytes and transported 
to dendritic cells via exosomes can trigger antigen-specific T-cell responses and provide a foundation 
to explore in more detail the relationship between expression of specific HLA alleles and the 
development of drug-induced liver injury. 
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Danger signals stimulate Toll-like receptors and NLRP3 and this results in dendritic cell maturation, 
which can be visualized by upregulation of cell surface receptors and cytokine secretion (40). 
Haptenic chemicals and certain drugs have also been shown to stimulate dendritic cell maturation in 
vitro (32). Thus, the final objective of this project was to determine whether dendritic cell uptake of 
hepatocyte-derived drug-modified proteins encapsulated within exosomes occurs silently or with a 
concurrent stress response.  The uptake of hepatic exosomes with or without drug treatment did not 
trigger increased dendritic cell surface receptor expression or cytokine release. These data show that 
drug-modified proteins can be transferred from tissue cells to the immune system via exosome 
transport to ultimately be displayed as peptide fragments on HLA molecules on the surface of 
dendritic cell without stimulating a stress response.  
 
To conclude, we have demonstrated a significant heterogeneity in the proteome of exosomes 
isolated from hepatocytes obtained from different individuals. Exosomes derived from nitroso 
sulfamethoxazole treated hepatocytes contained a subset of proteins with altered levels of 
representation, suggesting perturbation of the stress response in hepatocytes exposed to nitroso-
sulfamethoxazole. Furthermore, the drug-modified intracellular hepatic proteins transported by 
exosomes to dendritic cells serve as antigenic determinants for immune activation.  
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FIGURE LEGENDS 
Figure 1. Morphology and proteomic characterization of hepatocyte-derived exosomes. (A) 
Hepatocyte-derived exosomes measured ≤ 100 nm in diameter, scale bar = 50 nm. (B) CD63 
expression by hepatocyte-derived exosomes and corresponding whole cell lysates from 3 donors 
determined by immunoblotting using anti-CD63 specific antibody. (C) Proteins identified in 
hepatocyte-derived exosomes my mass spectrometry (n = 3). Dark bars represent total exosomal 
proteins identified across treatment groups and open bars represent human exosomal proteins 
published in the ExoCarta database. (D) Comparison of the whole liver tissue proteome with that of 
hepatocyte-derived exosomes based on molecular function, biological process, cellular component, 
protein class and pathway using PANTHER gene list analysis. 
 
Figure 2. Characterization of global drug-induced changes in proteins expressed by hepatocyte-
derived exosomes. (A) Hierarchical cluster analysis of data processed using approach 1 and batch 
corrected for hepatocyte donor. (B) Hierarchical cluster analysis of data processed using approach 2 
and batch corrected for hepatocyte donor. Green and red represent low and high protein levels, 
respectively. (C) PCA of data processed using approach 1 and batch corrected for hepatocyte donor. 
(D) PCA of data processed using approach 2 and batch corrected for hepatocyte donor.  (E) PANTHER 
molecular function classification of proteins differentially represented in exosomes from nitroso 
sulfamethoxazole-treated hepatocytes compared to those exposed to all other treatments. (F) 
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PANTHER protein class classification of proteins differentially represented in exosomes from nitroso 
sulfamethoxazole-treated hepatocytes compared to those exposed to all other treatments. 
 
Figure 3. Detection of drug modification of exosomal proteins derived from drug-treated 
hepatocytes from a single donor. (A) Western blot characterisation of human exosomal proteins 
modified by either nitroso sulfamethoxazole or flucloxacillin using-specific anti-drug antibodies. (B) 
MS/MS spectrum of amoxicillin-modified peptide from SOX30. (C) MS/MS spectrum of flucloxacillin-
modified peptide from HSA. (D) MS/MS spectrum of nitroso sulfamethoxazole-modified peptide 
from serotransferrin. Fragment ions derived from the drug are circled in red, the N-terminal y ion is 
circled in green (resulting from cleavage of the entire drug adduct prior to cleavage of the peptide 
backbone) and ions with full or partial drug adducts are marked with an asterisk.  
 
Figure 4. Exosomal proteins modified with drugs. (A) List of the exosomal proteins modified by 
nitroso sulfamethoxazole, flucloxacillin and amoxicillin and the specific sites of modification. (B-E) 
Three-dimensional structures of exosomal proteins showing the sites of drug modification: (B) HSA 
(PDB-1O9X)-amoxicillin, (C) HSA (PDB-1O9X)-flucloxacillin, (D) serotransferrin (PDB-1DTG)-
sulphinamide, (E) transthyretin (PDB-4N86)-N-hydroxysulphinamide.  
 
Figure 5. The uptake of unmodified and drug-modified hepatocyte-derived exosomes by human 
monocyte-derived dendritic cells. Exosomes derived from drug-treated hepatocytes were cultured 
with human monocyte-derived dendritic cells for 24 h and exosome uptake was evaluated using 
confocal microscopy. Scale bar represents 5 micrometres. Green = F-actin, Blue = nucleus, red = 
unmodified or drug-modified exosomes. (A) Uptake of unmodified hepatocyte-derived exosomes by 
dendritic cells. Exosomes were first stained red with PKH26 dye before 24 h culture with dendritic 
cells and confocal microscopy. (B, C) Uptake of flucloxacillin- and nitroso-sulfamethoxazole-modified 
hepatocyte-derived exosomes by dendritic cells, respectively. Exosomes derived from drug-treated 
hepatocytes were cultured with dendritic cells for 24 h and drug-specific antibodies were used to tag 
drug-modified exosomal proteins followed by confocal microscopy to determine the uptake of drug-
modified exosomes.  (D) Exosome uptake by dendritic cells in the absence of inhibitor. (E) The effect 
of latrunculin A (phagocytosis inhibitor) on dendritic cell exosome uptake. (F) Effect of dynasore 
(endocytosis inhibitor) on dendritic cell exosome uptake. (G) Combined effect of latrunculin A and 
dynasore on dendritic cell exosome uptake.   
 
Figure 6. Effect of hepatocyte-derived exosomes on dendritic cell surface marker expression. 
Dendritic cells were cultured with exosomes derived from either cell culture media-or drug-treated 
hepatocytes or soluble drugs for 24 h prior to analysis of (A-C) maturation markers (CD80, CD83, 
HLA-DR) and (D-E) activation markers (MHC class II, CD40) by flow cytometry. Dendritic cells were 
then stained with fluorochrome-conjugated antibodies and the expression of markers was evaluated 
using a FACS Canto II flow cytometer. A minimum of 10, 000 events were acquired. 
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Figure 7. LC-MS/MS characterization of an amoxicillin-modified HLA-A*02:01 binding peptide 
derived from transcription factor protein SOX30 and functional evaluation of T-cell 
immunogenicity. (A) SLLEPSVKI peptide design rationale. The tryptic peptide identified in exosomal 
proteins is highlighted in orange with the SOX30 amino acid sequence expanded to include 10 amino 
acids in either direction of the modified lysine. The HLA-A*02:01 binding epitope is highlighted in 
yellow labelled with the anchor residues in blue. The NetMHCpan score for this peptide was 0.047. 
(B) MS/MS Spectrum of the unmodified SLLEPSVKI peptide derived from SOX30. (C) MS/MS 
Spectrum of the amoxicillin modified SLLEPSVKI peptide derived from SOX30. Fragment ion peaks of 
the peptide sequence have been labelled with a red arrow and drug associated peaks labeled with a 
blue arrow. (D) Naïve T-cells from 3 HLA-A*02:01+ human donors were co-cultured with unmodified 
or amoxicillin-modified peptide-pulsed monocyte-derived dendritic cells at a 25:1 ratio in a 96 U-
bottomed plate (24-32 wells per condition), in a final volume of 200 µl for 14 days. Cultures were re-
stimulated with a fresh batch of autologous peptide loaded dendritic cells for 48 h. 3[H]-thymidine 
added during the final 16 h of culture to measure the extent of T-cell proliferation. Wells were 
harvested and incorporated radioactivity analyzed using a beta counter. Each data point represents 
proliferative T-cell responses in a single well of a 96 well plate. 
 
Supplementary Figure 1 
Venn diagram showing the overlap between proteins that were differentially packaged (ANOVA) in 
exosomes from nitroso sulfamethoxazole-treated hepatocytes compared to all other treatments 
revealed using approach 1 (blue) and approach 2 (red). 
 
Supplementary Figure 2 
Quantification of the degree of uptake of hepatocyte-derived exosomes by human dendritic cells. 
Images of dendritic cell uptake of hepatocyte-derived dendritic  cells were processed using ZEN 
imaging and Fiji software.  The amount of exosome taken up was estimated by selecting exosomes, 
represented by the red elements in the confocal microscopy images, within a representative 
dendritic cell in a field of view and the fluorescence intensity measured. (A) Uptake of either 
unmodified of drug-modified exosomes. (B) Effect of latrunculin A and dynasore on dendritic cell 
uptake of hepatocyte-derived exosomes.  
 
Supplementary Figure 3 
Optimisation of amoxicillin-modified peptide purification using reversed phase HPLC. Purification of 
the SLLEPSVK(Amox)I from free drug and other contaminants was optimised by performing a series 
of HPLC experiments. Peptides were incubated with drug at a 50:1 molar ratio in 70%ACN/ 30%H2O 
for 48 hours at 37oC. Analytes were loaded onto a Phenomenex C18 Kinetex 5µm column and 
analysed using an Agilent 1200 HPLC at λ214. (A) Unmodified Fmoc-SLLEPSVKI peptide alone at 5mM 
concentration prior to incubation. (B) Amoxicillin alone at 250mM concentration prior to incubation. 
Penicillins are prone to degradation in water, thus several degradation peaks are observed. (C) 
Fmoc-SLLEPSVKI incubated with amoxicillin after 5 minutes labelled with amoxicillin peaks and the 
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unmodified Fmoc-protected peptide peaks. (D) Fmoc-SLLEPSVKI incubated with amoxicillin after 4 
hours, labelled with the amoxicillin-modified fmoc-peptide peak. (E) Fmoc-SLLEPSVKI incubated with 
amoxicillin after 24 hours, labelled with the amoxicillin-modified fmoc-peptide peak. (F) Fmoc-
SLLEPSVKI incubated with amoxicillin after 48 hours, labelled with the amoxicillin-modified fmoc-
peptide peak. (G) Fmoc-SLLEPSVK[AX]I alone after purification and collection. Some amoxicillin 
dimer modified peptide is observed. (H) Amoxicillin-modified peptide following piperidine 
incubation. (I) Final product of deprotected SLLEPSVK[AX]I used for cell culture studies. 
 
 
Supplementary Table 1 
List of proteins identified in hepatocyte exosomes. LC-MS/MS data were acquired on a Triple TOF 
6600 and processed using ProteinPilot 5. All proteins lie within a 1% FDR. The proteins are listed in 
order of their confidence.  
 
Supplementary Table 2 
List of exosomal proteins associated with treatment of hepatocytes with nitroso sulfamethoxazole. 
ANOVA analysis was performed to compare the protein profile of the nitroso sulfamethoxazole-
treated samples to all the others. This identified 148 proteins from approach 1 and 113 proteins 
from approach 2 that were significantly (P<0.05) associated with the nitroso-sulfamethoxazole 
treatment. Thirty five of these proteins were present in both datasets and are listed here. 
 
Supplementary Table 3 
List of exosomal proteins associated with treatment of hepatocytes with individual drugs. ANOVA 
analysis was performed to compare the protein profile of each of the drug-treated samples to the 
control sample. (A) Amoxicillin. (B) Flucloxacillin. (C) Isoniazid. (D) Nitroso-sulfamethoxazole. The 
shaded proteins in D correspond to proteins also highlighted in the comparison between nitroso-
sulfamethoxazole sample and all other treatments combined listed in Supplementary Table 2. 
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Figure 4 
 
 
 
 
 
 
S/No. Drug Exosomal proteins modified Peptides modified
1. Amoxicillin Human transcription factor, SOX30
Human serum albumin
Human apolipoprotein E
305SVK(AMOX)IETK311
182LDELRDEGK(AMOX)ASSAK195
19K(AMOX)VEQAVETEPEPELR33
2. Flucloxacillin Human serum albumin 539ATK(FLU)EQLK545
182LDELRDEGK(FLU)ASSAK195
525KQ(FLU)TALVELVK534
3. SMX-NO Human serotransferrin
Human transthyretin
260C(sulphinamide)HLAQVPSHTVVAR273
24T(Me)VRWC(sulphinamide)AVSEHEATK37
1GPTGTGESKC(N-
hydroxysulphinamide)PLM(Ox)VK25
4. Isoniazid No protein adducts identified -
A.
HSA-Amoxicillin adduct
K525
K190
K541
K190
HSA-Flucloxacillin adduct
C28
C260 C10
Serotransferrin-SMX-NO adduct Transthyretin-SMX-NO adduct
B. C.
D. E.
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Figure 5 
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modified exosomes
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B. C.
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Control (No inhibitor)
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+ Dynasore (100 uM)
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+ Lat A (10 nM)
+ Exosomes
+ Dynasore (15 uM)
+ Exosomes
+ Lat A (1 uM)
+ Dynasore (100 uM)
+ Exosomes
D.
E. F.
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Figure 6 
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Figure 7 
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